

P-8972-US

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Application Number</td> <td>10/585,928</td> </tr> <tr> <td>Filing Date</td> <td>July 13, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>ZIV, Ilan</td> </tr> <tr> <td>Art Unit</td> <td>1615</td> </tr> <tr> <td>Examiner Name</td> <td>SAMALA, JAGADISHWAR RAO</td> </tr> <tr> <td>Attorney Docket Number</td> <td>P-8972-US</td> </tr> </table>		Application Number	10/585,928	Filing Date	July 13, 2006	First Named Inventor	ZIV, Ilan	Art Unit	1615	Examiner Name	SAMALA, JAGADISHWAR RAO	Attorney Docket Number	P-8972-US
Application Number	10/585,928														
Filing Date	July 13, 2006														
First Named Inventor	ZIV, Ilan														
Art Unit	1615														
Examiner Name	SAMALA, JAGADISHWAR RAO														
Attorney Docket Number	P-8972-US														
Sheet	2	of	2												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/J.S./	F	GERSHON H. Organic fluorine compounds.II., Journal of Medicinal Chemistry 1967, p. 186-188, vol. 10, no. 2, American Chemical Society	<input type="checkbox"/>
	G	BEVERS, E.M., et al., Lipid translocation across the plasma membrane of mammalian cells, Biochimica et Biophysica Acta 1439 (1999) 7-330 Elsevier	<input type="checkbox"/>
	H	BOMBELI, T., et al, Apoptotic Vascular Endothelial Cells Become Procoagulant, Blood, April, 1997, pp 2429-2442, Vol 89, No 7, American Society of Hematology, Washington DC	<input type="checkbox"/>
	I	BRATTON, D.L., et al, Appearance of Phosphatidylserine on Apoptotic Cells Requires Calcium-mediated Nonspecific Flip-Flop and Is Enhanced by Loss of the Aminophospholipid Translocase, The Journal Of Biological Chemistry, October 15, 1997, pp. 26159-26165, Vol. 272, No. 42, The American Society for Biochemistry and Molecular Biology, Inc.	<input type="checkbox"/>
	J	BURSCHE, W., et al, Cell death by apoptosis and its protective role against disease, Trends Pharmacol Sci. 1992 Jun;13(6):245-51.	<input type="checkbox"/>
	K	KOCKX M.M., et al, Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res. 2000;736-746, vo. 45, Elsevier	<input type="checkbox"/>
	L	MALLAT, Z., et al, Colocalization of CPP-32 With Apoptotic Cells in Human Atherosclerotic Plaques Circulation, 1997;124-428 Vol. 96, American Heart Association, Inc.	<input type="checkbox"/>
	M	MARTIN, S., et al, Early Redistribution of Plasma Membrane Phosphatidylserine Is a General Feature of Apoptosis Regardless of the Initiating Stimulus: Inhibition by Overexpression of Bcl-2 and Abl, J. Exp.Med, November 1995; 1545 Vol. 182	<input type="checkbox"/>
	N	PUGSLEY, W., et al, The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning, Stroke 1994; 1393-1399, Vol 25, American Heart Association	<input type="checkbox"/>
	O	SIMS, P.J., et al, Unraveling the Mysteries of Phospholipid Scrambling Thromb. Haemost. 2001; p. 266-75, Vol. 86, Schattauer GmbH, Stuttgart	<input type="checkbox"/>
	P	STARY, H.C., et al, A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis, Circulation, 1988; p. 1355-1374, Vol. 92, American Heart Association, Inc.	<input type="checkbox"/>
/J.S./	Q	VAN DEN EUNDE, S.M., et al, Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis, Cell Death Differentiation, 1997; p. 311-316, Vol. 4, Stockton Press	<input type="checkbox"/>

Examiner Signature	/Jagadishwar Samala/ (04/15/2010)	Date Considered	
--------------------	-----------------------------------	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.